Company: ARWR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001628280-25-004634
Chunk: 75

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 8
Chunk 75
---
678 9,000 Less: Unamortized debt discount and issuance costs(15,264)(15,817)Less: Current portion of credit facility(1,625)$— Credit facility, net of current portion$407,789 $393,183 The following table sets forth total interest expense recognized related to the Credit Facility:Three Months Ended December 31,20242023(in thousands)Amortization of debt discount and issuance costs$553 $— Contractual interest expense15,678 — Total interest expense$16,231 $— 

NOTE 13. NET LOSS PER SHARE

The following table presents the computation of basic and diluted net loss per share.                            Three Months Ended December 31,20242023(in thousands, except per share amounts)Numerator:Net loss attributable to Arrowhead Pharmaceuticals, Inc.$(173,085)$(132,864)Denominator:Weighted-average basic shares outstanding (1)124,848 107,415 Effect of dilutive securities— — Weighted-average diluted shares outstanding (1)124,848 107,415 Basic net loss per share$(1.39)$(1.24)Diluted net loss per share$(1.39)$(1.24)(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.The following table sets forth the potentially dilutive securities that have been excluded from the calculation of 

20

diluted net loss per share because to include them would be anti-dilutive.Three Months Ended December 31,20242023(in thousands)Options739 718 Restricted stock units3,845 2,826 Total4,584 3,544 

NOTE 14. SUBSEQUENT EVENTS

As previously disclosed, on November 25, 2024, the Company and Sarepta entered into the Sarepta Collaboration Agreement for the co-development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. The Company also entered into a Stock Purchase Agreement with an affiliate of Sarepta for a private placement of shares of common stock of the Company. On February 7, 2025, after receipt of clearance under the Hart-Scott Rodino Antitrust Improvements Act, the transactions contemplated by the Sarepta Collaboration Agreement and the Stock Purchase Agreement closed. Upon closing, the Company